Skip to content
Nonprofiteer
← All organizations

EVERSIGHT

EIN 38-2117115 ANN ARBOR, MI

Revenue 2024
$34,039,876
Expenses 2024
$30,603,995

Program services were 79.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

As filed

Subsection
03
Classification
8000
Street
3985 RESEARCH PARK DR

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

Mission

Eversight's mission is to restore sight and prevent blindness through the healing power of donation, transplantation and research. Blinding eye diseases affect 80 million Americans. That means millions of people cannot see their loved ones, drive to work or read the newspaper on a Sunday morning. Their vision loss results in an economic impact of $51.4 billion every year in the United States alone. Eversight envisions a world without blindness-a world where all mothers can see their children and all children can grow up to lead independent, productive lives through the gift of sight. To make vision a reality for all, Eversight continuously works to expand its reach, connect more effectively with communities in need and provide the gift of sight to everyone.

Activities or mission (Part I)

Eversight is a 501(c)3 nonprofit organization with the mission to restore sight and prevent blindness through the healing power of donation, transplantation and research. The Eversight network is responsible for recovering, evaluating and providing human eye tissue for transplantation; advancing research into the causes and cures of blinding eye conditions; promoting donation awareness through public and professional education; and providing humanitarian aid to people around the world in need of corneal transplantation. Founded in 1947, Eversight maintains its commitment to excellence as an accredited member of the Eye Bank Association of America (EBAA) and by meeting the highest quality standards set by the U.S. Food and Drug Administration. The nonprofit operates 24/7/365 in Connecticut, Illinois, Michigan, New Jersey, Ohio and South Korea, and collaborates with surgeons, researchers, academic medical centers and eye banks across the United States and abroad. Eversight works with the

  • RESORING SIGHT Eversight continues to take meaningful steps toward transforming the future of vision care by supporting sustainable eye banking infrastructure and providing priceless clinical education. In 2024, Eversight provided the gift of sight to more than 10,200 people across the United States and around the world. Eversight provided 59 corneas for sight-restoring transplants gratis or at a reduced fee for uninsured patients.Eversight's work began in 1947 with the establishment of the fourth eye bank in the United States, then known as the Illinois Eye-Bank. Over time, nonprofit eye banks were established in every state to meet the critical demand for corneal tissue to treat preventable blindness.In 1985, the Illinois Eye-Bank and Michigan Eye-Bank formed a partnershipone that would earn a reputation for clinical excellence made possible by some of the finest medical directors, staff and board members in the eye banking field. The success of the organization attracted affiliations with other regional eye banks forming one of the largest networks of eye banks in the U.S. In 2015, the network became known as Eversight, all working together as a unified operation to deliver the highest quality services to surgeons and their patients and to continue to grow our impact around the world.Eversight provided more than 14,900 tissues for transplantation, research and education globally in 2024. We worked or placed tissue with physicians and researchers in 34 countries and facilitated training for 918 clinicians. Together with all our partnersadvocates, donor families, transplant recipients, surgeons, Lions, fellow eye banks, healthcare leaders, philanthropic supporters and many otherswe were able to make vision a reality for more people worldwide.

    Expenses $23,033,157 · Revenue $28,388,552

  • FINDING A CURE In the pursuit of eliminating blinding eye diseases, Eversight established the Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, to provide leading ophthalmology researchers with the resources they need to find cures and treatments for eye diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma. Eversight provided more than 4,700 tissues for research and education purposes in 2024. Our in-house research team also provided Eversight partners with valuable research and development services and pioneered new eye banking practices.Since 2014, the Eversight researchers have authored 50 publications and given 34+ presentations at international conferences. The team published six publications in 2024 on: comparing cornea storage medias, perceptions of cornea and eye donation, automated counting and density of donor endothelial cells, protocol for corneal stromal stem cell cultivation, using trypan blue for cell viability after preloading DMEK grafts, and docosahexaenoic acid in diabetic humans and mice. With our many academic partners, Eversight researchers have contributed to over 250 peer-reviewed scientific papers that have garnered 6,300 citations and counting.Eversight has a longstanding track record of research and development, having awarded more than $4 million in grants to date that stimulate pioneering clinical and basic science research aiming to develop new ways to restore sight, prevent blindness and ultimately help patients live life to the fullest. Since 1980, our Eye & Vision Research Grant Program has supported researchers at leading academic medical institutions including Harvard, Tufts, Cleveland Clinic, Case Western Reserve, University of Michigan, Northwestern and more. By design, Eversight's grant program provides critical, early-stage funding that is intended to drive foundational research and discovery. Many of these projects have stimulated larger-scale studies and won further financial support from the National Institutes of Health.In the 2025 funding cycle, Eversight awarded four grants at Loyola University Chicago, University of Houston, University of Illinois Chicago and University of Michigan to advance studies to investigate developing a novel drug evaluation system to stimulate blood vessel growth experimentally using factors that have been linked to the pathophysiology of both wAMD and PDR; enhancing limbal stem cell preservation; understanding the biomechanics of keratoconus by looking at the composition and microstructure of normal human and keratoconus corneal extracellular matrix; and advancing therapies for ocular surface squamous neoplasia. Each year, recipients are selected by an independent review panel of academic researchers and ophthalmologists. This distinguished panel awards proposals that encourage meaningful scientific inquisition and align with Eversight's mission to restore sight and prevent blindness through the healing power of donation, transplantation and research.

    Expenses $193,609 · Grants $60,000 · Revenue $75,664

  • SUSTAINABLE INTERNATIONAL IMPACTEversight works to eliminate corneal blindness worldwide through eye bank development, clinical training and tissue provision. With more than 75 years of eye banking expertise, we deliver both short- and long-term solutions to transform the lives of more than 12 million people suffering from corneal blindness globally. In 2024, Eversight International provided more than 4,200 tissues for transplant and worked with surgeons in 33 countries outside the United States, making the gift of sight possible for many in need. Eversight provided 76 cornea tissues for sight-restoring transplants gratis or at a reduced rate for medical missions and uninsured patients outside the United States.In medically underserved areas, Eversight Global Development fosters authentic relationships with local leaders to establish culturally informed eye donation frameworks and sustainable eye banking infrastructure. Our experienced team offers vital clinical training and education to eye surgeons and eye bank technicians on the latest clinical methods, improving access to life-changing transplants. Through the incredible generosity of our donors and donor families, Eversight Global Development also provides corneal tissue from the United States for transplant and research globally, providing hope for the future and restoring sight to patients in need. Our global mission is informed by and aligns with the United Nations Sustainable Development Goals (SDGs), with particular attention given to: #3 Good Health and Well-being, #4 Quality Education, #8 Decent Work and Economic Growth, #10 Reduced Inequalities and #11 Sustainable Cities & Communities. According to the World Health Organization, every dollar spent on improving eye health in underdeveloped areas generates a four-fold return on investment. To address systemic unmet need, Eversight actively works with medical professionals, governments, vision health organizations and other NGOs in regions lacking eye banks and infrastructure, including United Arab Emirates, Pakistan and South Korea. With proven eye banking and technical training practicesand having played a part in the elimination of the U.S. cornea transplant waiting listEversight is uniquely qualified to work with countries lacking transplant programs to help them establish national networks for eye banking and cornea donation with culturally appropriate donation models and state-of-the-art clinical capabilities.Globally, an estimated 2.2 billion people are impacted by blindness and visual impairment. Ninety percent of vision-impaired people live in low- and middle- income countries. Approximately one billion of these individuals are coping with blindness or visual impairment that can be characterized as preventable or not sufficiently addressed. Vision loss results in substantial economic impact worldwide due to the inability of people who are vision impaired to contribute to their fullest in their communities. Eversight envisions a world without blindnessa world where all people in every community can lead independent, productive lives through the gift of sight. While providing for immediate global cornea transplant needs with U.S. donor tissue, Eversight continues to address the global burden by empowering international communities to take meaningful, sustainable steps every day to make vision a reality for all.

    Expenses $1,062,560 · Revenue $2,108,316

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • Patty Jo Herndon

    Imm. Past Chair

    Total calculated
    $0
    Hours/week
    1

  • Kathy L Zelenock

    Chair

    Total calculated
    $0
    Hours/week
    1

  • Joseph M Maiuri

    Treasurer

    Total calculated
    $0
    Hours/week
    1

  • Mahmoud N Ghazzi MD PhD

    Secretary

    Total calculated
    $0
    Hours/week
    1

  • Lorenzo Cervantes MD

    Director

    Total calculated
    $0
    Hours/week
    1

  • Jonathan Lass MD

    Director

    Total calculated
    $0
    Hours/week
    1

  • Shahzad Mian MD

    Director

    Total calculated
    $0
    Hours/week
    1

  • Carol Cunningham MD

    Director

    Total calculated
    $0
    Hours/week
    1

  • Probi Kapur

    Director

    Total calculated
    $0
    Hours/week
    1

  • Carolyn M Welsh

    Vice-Chair

    Total calculated
    $0
    Hours/week
    1

  • Sandra Fletcher

    Director

    Total calculated
    $0
    Hours/week
    1

  • Peter Wroblewski

    Director

    Total calculated
    $0
    Hours/week
    1

  • Jill Maher MA COE

    Director

    Total calculated
    $0
    Hours/week
    1

  • John Ryan

    Director

    Total calculated
    $0
    Hours/week
    1

  • Diane Hollingsworth

    President & CEO

    Total calculated
    $337,411
    From this org
    $302,974
    From related orgs
    $0
    Other
    $34,437
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $302,974
    Bonus
    $0
    Other
    $0
    Deferred
    $18,128
    Nontaxable benefits
    $16,309
    Filer's total
    $337,411

  • Michael O'Keefe

    Chief Operations Officer

    Total calculated
    $238,923
    From this org
    $209,314
    From related orgs
    $0
    Other
    $29,609
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $209,314
    Bonus
    $0
    Other
    $0
    Deferred
    $13,300
    Nontaxable benefits
    $16,309
    Filer's total
    $238,923

  • Julie Collins

    Chief Finance & Administrative Officer

    Total calculated
    $245,459
    From this org
    $215,850
    From related orgs
    $0
    Other
    $29,609
    Hours/week
    50 + 8 related

    Schedule J breakdown matched by us

    Base
    $215,850
    Bonus
    $0
    Other
    $0
    Deferred
    $13,300
    Nontaxable benefits
    $16,309
    Filer's total
    $245,459

  • Michael Titus

    Sr. VP, Clinical Services

    Total calculated
    $252,781
    From this org
    $218,538
    From related orgs
    $0
    Other
    $34,243
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $218,538
    Bonus
    $0
    Other
    $0
    Deferred
    $13,831
    Nontaxable benefits
    $20,412
    Filer's total
    $252,781

  • Bret Hopman

    SR. VP, Marketing & Communications

    Total calculated
    $198,430
    From this org
    $165,861
    From related orgs
    $0
    Other
    $32,569
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $165,861
    Bonus
    $0
    Other
    $0
    Deferred
    $12,157
    Nontaxable benefits
    $20,412
    Filer's total
    $198,430

  • Onkar Sawant

    VP, Research & Innovations

    Total calculated
    $181,552
    From this org
    $168,441
    From related orgs
    $0
    Other
    $13,111
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $168,441
    Bonus
    $0
    Other
    $0
    Deferred
    $10,711
    Nontaxable benefits
    $2,400
    Filer's total
    $181,552

  • Caitlin Lopes

    Partner Relations Director

    Total calculated
    $159,276
    From this org
    $126,027
    From related orgs
    $0
    Other
    $33,249
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $126,027
    Bonus
    $0
    Other
    $0
    Deferred
    $8,983
    Nontaxable benefits
    $24,266
    Filer's total
    $159,276

  • Catherine McClory

    Director, Compliance & Quality Assurance

    Total calculated
    $169,975
    From this org
    $157,251
    From related orgs
    $0
    Other
    $12,724
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $157,251
    Bonus
    $0
    Other
    $0
    Deferred
    $10,324
    Nontaxable benefits
    $2,400
    Filer's total
    $169,975

  • Indu Vadakkepattath

    Data Scientist/Applications Manager

    Total calculated
    $162,454
    From this org
    $150,320
    From related orgs
    $0
    Other
    $12,134
    Hours/week
    50

    Schedule J breakdown matched by us

    Base
    $150,320
    Bonus
    $0
    Other
    $0
    Deferred
    $9,734
    Nontaxable benefits
    $2,400
    Filer's total
    $162,454

  • Joseph Zullo

    Manager, Information Technology

    Total calculated
    $131,466
    From this org
    $114,985
    From related orgs
    $0
    Other
    $16,481
    Hours/week
    50

  • Kara Kelley

    Partner Relations Director

    Total calculated
    $119,354
    From this org
    $109,886
    From related orgs
    $0
    Other
    $9,468
    Hours/week
    50

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

  • 2024
    Revenue
    $34,039,876
    Expenses
    $30,603,995
    Contributions
    $1,166,781
    Grants paid
    $60,000
  • 2023
    Revenue
    $30,662,355
    Expenses
    $27,526,933
    Contributions
    $1,283,375
    Grants paid
    $0
  • 2022
    Revenue
    $25,488,101
    Expenses
    $24,016,038
    Contributions
    $864,304
    Grants paid
    $0

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $28,194,670
    Expenses
    $23,635,626
    Assets (EOY)
    $41,315,497

  • 2020 · 990

    Revenue
    $20,997,119
    Expenses
    $20,473,565
    Assets (EOY)
    $36,782,737

  • 2019 · 990

    Revenue
    $22,878,172
    Expenses
    $21,673,490
    Assets (EOY)
    $33,975,355

  • 2018 · 990

    Revenue
    $22,860,854
    Expenses
    $22,616,869
    Assets (EOY)
    $24,200,521

  • 2016 · 990

    Revenue
    $17,302,734
    Expenses
    $17,881,137
    Assets (EOY)
    $25,553,796

  • 2015 · 990

    Revenue
    $18,149,472
    Expenses
    $16,984,688
    Assets (EOY)
    $58,871,446

  • 2015 · 990

    Revenue
    $16,801,666
    Expenses
    $15,648,760
    Assets (EOY)
    $58,859,568

  • 2014 · 990

    Revenue
    $24,501,913
    Expenses
    $23,299,225
    Assets (EOY)
    $44,166,181

  • 2013 · 990

    Revenue
    $23,071,646
    Expenses
    $23,367,522
    Assets (EOY)
    $37,060,830

  • 2012 · 990

    Revenue
    not reported
    Expenses
    $24,620,556
    Assets (EOY)
    $30,687,918

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

No itemized grants to organizations. Schedule I is filed only by organizations that granted more than $5,000 to a recipient, so most filers have none.

Grants received

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Declared on its 2024 return

Declared as related by

Taxable family

From Schedule R Parts I, III and IV: entities that legally are the filer, and taxable partnerships, corporations and trusts it is related to. These record ownership and control, not shared board members or money.

Related corporations and trusts on its 2024 return

  • Eversight Korea LLC

    C · Eye Bank · KS

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Listed as of 13 October 2026, under deductibility PC.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 13 October 2026 and read 29 October 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.